News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
New Board of Directors and management team at Suven Pharma also appointed
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
Subscribe To Our Newsletter & Stay Updated
